Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Inotiv, Inc. NOTV
$5.76
-$0.71 (-12.27%)
На 18:01, 12 мая 2023
+56.25%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
160451312.00000000
-
week52high
27.22
-
week52low
3.65
-
Revenue
547656000
-
P/E TTM
0
-
Beta
2.48754300
-
EPS
-13.63000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 20:00
Описание компании
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Lake Street | Buy | Buy | 11 авг 2022 г. |
| Lake Street | Buy | 31 янв 2022 г. | |
| Craig-Hallum | Buy | 20 сент 2021 г. | |
| Jefferies | Buy | 04 окт 2022 г. | |
| Lake Street | Hold | Buy | 18 ноя 2022 г. |
| Lake Street | Buy | Hold | 11 янв 2023 г. |
| Jefferies | Hold | Buy | 19 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Freeman Jeffrey Brennan | A | 4817 | 4142 | 18 янв 2023 г. |
| Beattie John Gregory | A | 58795 | 7101 | 18 янв 2023 г. |
| Krupp Jeffrey Arthur | A | 11065 | 5000 | 18 янв 2023 г. |
| Krupp Jeffrey Arthur | A | 6065 | 1065 | 18 янв 2023 г. |
| Leasure Robert Jr. | A | 693703 | 59172 | 18 янв 2023 г. |
| Sagartz John E | A | 686947 | 5917 | 18 янв 2023 г. |
| Taylor Beth | A | 89792 | 5917 | 18 янв 2023 г. |
| Garrett Michael | A | 11467 | 9467 | 18 янв 2023 г. |
| Beraldi Fernanda | A | 5340 | 2840 | 18 янв 2023 г. |
| Pitchford William D | D | 74051 | 2123 | 09 дек 2022 г. |
Новостная лента
Inotiv, Inc. (NOTV) Q2 2023 Earnings Call Transcript
Seeking Alpha
11 мая 2023 г. в 20:50
Inotiv, Inc. (NASDAQ:NOTV ) Q2 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Devin Sullivan – Investor Relations-The Equity Group Bob Leasure – President and Chief Executive Officer Beth Taylor – Chief Financial Officer Conference Call Participants Matt Hewitt – Craig-Hallum Dave Windley – Jefferies Frank Takkinen – Lake Street Capital Markets Operator Good afternoon, and welcome to Inotiv's Second Quarter Fiscal 2023 Financial Results Conference Call. At this time all participants are in listen-only mode.
Inotiv, Inc. to Report Fiscal 2023 Second Quarter Financial Results and Host Conference Call on Thursday, May 11, 2023
GlobeNewsWire
26 апр 2023 г. в 08:33
WEST LAFAYETTE, Ind., April 26, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 second quarter ended March 31, 2023, on Thursday, May 11, 2023, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
Inotiv, Inc. (NOTV) Q1 2023 Earnings Call Transcript
Seeking Alpha
13 февр 2023 г. в 21:22
Inotiv, Inc. (NASDAQ:NOTV ) Q1 2023 Earnings Conference Call February 13, 2023 4:30 PM ET Company Participants Devin Sullivan - The Equity Group Inc. Bob Leasure - President and Chief Executive Officer Beth Taylor - Senior Vice President and Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Frank Takkinen - Lake Street Capital Markets David Windley - Jefferies Tim Daley - Wells Fargo Operator Hello, and welcome to Inotiv Inc.'s First Quarter Fiscal 2023 Financial Results Conference Call and Webcast. A question-and-answer session will follow the formal presentation.
Inotiv, Inc. to Report Fiscal 2023 First Quarter Financial Results and Host Conference Call on Monday, February 13, 2023
GlobeNewsWire
06 февр 2023 г. в 22:45
WEST LAFAYETTE, Ind., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 first quarter ended December 31, 2022 on Monday, February 13, 2023 after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
Inotiv: Turning Focus To Organic Growth
Seeking Alpha
17 янв 2023 г. в 04:28
The stock may have found its bottom in December 2022. Revenue jumped 400 percent in the fourth fiscal quarter, but earnings plummeted.